title: Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.
abstract: BACKGROUND
  Clobetasol propionate 0.05% spray is available for treating moderate-to-severe plaque psoriasis; however, there is limited information with plaque psoriasis of the scalp.
  
  
  OBJECTIVE
  Evaluate the efficacy, safety, and quality-of-life impact of clobetasol propionate 0.05% spray in patients with moderate to severe plaque psoriasis of the scalp.
  
  
  METHODS
  Multicenter, randomized, double-blind, vehicle-controlled study involving 81 men and women with moderate-to-severe (Global Severity Score [GSS] = 3 or 4) plaque psoriasis of the scalp. Eligible patients were treated with clobetasol propionate 0.05% spray or vehicle spray, which was applied twice daily for up to four weeks. The primary efficacy end point was the GSS of psoriasis of the scalp after four weeks. Safety assessments included local tolerability, presence of Cushing's syndrome, and adverse events.
  
  
  RESULTS
  At the end of treatment, 85 percent (35/41) of patients in the clobetasol propionate 0.05% spray group achieved success (GSS clear or almost clear), compared with 13 percent (5/40) in the vehicle spray group (P is less than .001). The proportion of patients treated with clobetasol propionate 0.05% spray who achieved a rating of clear (GSS = 0) after two weeks and at the end of treatment was 12 percent and 51 percent, respectively. Clobetasol propionate 0.05% spray was well tolerated, and there were no serious adverse events or reported cases of folliculitis or Cushing's syndrome.
  
  
  CONCLUSIONS
  Treatment with clobetasol propionate 0.05% spray for up to four weeks is effective and well tolerated for moderate-to-severe plaque psoriasis of the scalp.
authors.affiliation: Dermatology Research Associates, Los Angeles, CA, USA.
authors.forename: Howard
authors.initials: H
authors.lastname: Sofen
authors.forename: Charles P
authors.initials: CP
authors.lastname: Hudson
authors.forename: Fran E
authors.initials: FE
authors.lastname: Cook-Bolden
authors.forename: Norman
authors.initials: N
authors.lastname: Preston
authors.forename: Luz E
authors.initials: LE
authors.lastname: Colón
authors.forename: Luz E
authors.initials: LE
authors.lastname: Colón
authors.forename: Scott W
authors.initials: SW
authors.lastname: Caveney
authors.forename: Ronald W
authors.initials: RW
authors.lastname: Gottschalk
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002990:Clobetasol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003480:Cushing Syndrome / Q000209:etiology; D018450:Disease Progression; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D012535:Scalp / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D002990:Clobetasol